Prevention of stroke and systemic embolism with rivaroxaban compared with warfarin in patients with non-valvular atrial fibrillation and moderate renal impairment
Keith A.A. Fox(University of Edinburgh), Robert M. Califf(Duke University), Graeme J. Hankey, Daniel E. Singer(Massachusetts General Hospital), Jonathan P. Piccini(Clinical Research Institute), Kenneth W. Mahaffey(Cardiovascular Institute of the South), John F. Paolini(Synta Pharmaceuticals (United States)), Christopher C. Nessel(Johnson & Johnson (United States)), Jonathan L. Halperin(Icahn School of Medicine at Mount Sinai), Richard C. Becker(University of Cincinnati), Daniel Wojdyla, Manesh R. Patel(Duke University)
Cited by 614
Related Papers
Rivaroxaban versus Warfarin in Nonvalvular Atrial Fibrillation
|New England Journal of Medicine|2011|9.4k
Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes
|New England Journal of Medicine|2017|7.7k
Ticagrelor versus Clopidogrel in Patients with Acute Coronary Syndromes
|New England Journal of Medicine|2009|7.1k
ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation
|European Heart Journal|2012|6.8k
Prevalence of Diagnosed Atrial Fibrillation in Adults
|JAMA|2001|6.2k